Tarivid

Quick links to important sections

Tarivid

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tarivid

Property Description
Active ingredient Ofloxacin
Form Tablet, Solution (Ophthalmic/Otic Drops)
Pharmacological class Fluoroquinolone Antibiotic
Common use Bacterial Infections
Origin Synthetic

Tarivid is a synthetic, prescription-only medication that acts as a potent antibiotic to treat various infections caused by susceptible bacteria. Its identity is defined by its sole active ingredient, Ofloxacin, which is recognized for its broad-spectrum activity and clinically recognized for its effectiveness against hard-to-reach infections.


Definition, Origin, and Pharmacological Class

Tarivid is the name applied to the pharmaceutical product containing the core compound Ofloxacin, a substance that classifies it as a fluoroquinolone antibiotic. Ofloxacin is designed to fight bacterial pathogens effectively. This type of anti-infective agent is entirely synthetic in origin, unlike antibiotics derived from natural sources, and is known for its broad-spectrum efficacy against a wide range of bacteria. Ofloxacin is recognized for its role in the treatment landscape due to its robust activity against common bacterial strains.


Compositional Identity and Available Dosage Forms

The medicine is manufactured as a single-ingredient product, with its precise composition centered entirely on Ofloxacin, which is a racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. Tarivid is prepared in several dosage forms to accommodate different patient needs: these primarily include tablets for oral (systemic) administration, and specialized solutions for localized topical delivery, such as ophthalmic and otic drops. Ofloxacin is recognized as a core medicine due to its established efficacy in treating infections. This status signifies the drug's importance and verified utility in global health systems.


General Purpose and Action as a Bactericidal Agent

The general therapeutic purpose of Tarivid is to address and resolve established bacterial infections. For example, it is typically used in scenarios where a proven broad-spectrum agent is required to ensure complete eradication of the pathogen. It achieves this through a powerful and definitive bactericidal effect, meaning it actively kills susceptible bacteria rather than merely inhibiting their growth. This action works by blocking the function of essential bacterial enzymes, specifically DNA gyrase and topoisomerase IV, which are vital for the pathogen's DNA replication and repair, effectively eliminating the microbe responsible for the ailment.

Regulatory References

  1. Ofloxacin - StatPearls - NCBI Bookshelf - NIH
  2. NIH Ofloxacin StatPearls
  3. WHO Essential Medicines List for Ofloxacin

What side effects are possible with Tarivid?

Tarivid: Possible side effects and safety information

Tarivid (Ofloxacin) is associated with a risk profile that includes disabling and potentially irreversible serious adverse reactions, as documented by regulatory authorities (EMA/FDA). These severe reactions may affect multiple systems, including the musculoskeletal, nervous, psychiatric, and sensory systems.

Adverse effects are formally classified by frequency and grouped into System-Organ Classes (SOCs) in official labeling:


Regulatory Classification of Adverse Reactions

Frequency Classification Examples of Documented Effects
Common Nausea, vomiting, diarrhea, headache, insomnia
Uncommon Change or loss of taste, abdominal discomfort
Rare Tendinitis, psychotic reactions, photosensitisation, hepatic necrosis

Serious Adverse Reactions

The label specifies risks including tendinitis and tendon rupture, peripheral neuropathy (nerve damage), and severe Central Nervous System effects like seizures or toxic psychosis. Serious cardiac events such as aortic aneurysm, dissection, and heart valve regurgitation are also documented. Severe systemic reactions, including anaphylaxis (allergic shock) and Clostridioides difficile-associated diarrhea (CDAD), are reported.

Population and Time-Related Safety Notes

The risk of tendon rupture is noted to be increased in older adults, individuals with renal impairment, and those with organ transplants. Importantly, some severe adverse events, such as tendon damage or peripheral neuropathy, may occur soon after beginning treatment or up to several months after stopping the medication. The co-administration of systemic corticosteroids is associated with an increased risk of tendon damage.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Tarivid (Ofloxacin) requires that patients seek immediate medical attention for suspected overdosage. Management is stipulated as exclusively symptomatic and supportive, as no specific antidote is known.

The clinical signs of acute excess documented in regulatory labeling primarily affect the central nervous and gastrointestinal systems.

Documented Overdose Manifestations
CNS Effects: Tremors, Seizures, Headache, Confusion, Hallucinations.
GI Effects: Severe Nausea and Vomiting.

Overdosage presents a risk for several severe, potentially life-threatening outcomes. The labeling warns of ECG QT interval prolongation, which can lead to serious ventricular arrhythmia such as Torsades de pointes. Further risks include renal failure (often evidenced by crystalluria) and life-threatening hepatic failure. To prevent drug accumulation and toxicity, dosage must be adjusted in patients with renal impairment. Supportive procedures like gastric lavage or dialysis may be implemented depending on the time since ingestion and the patient's condition.

Therapeutic Uses of Tarivid

What Tarivid Treats: Main Uses and Benefits

Tarivid is commonly used across conditions presenting with systemic or localized discomfort, such as Urinary Tract Infections (UTIs), prostatitis, and acute lower respiratory infections (e.g., specific cases of pneumonia or bronchitis exacerbations). The medication is applied in contexts where an established bacterial cause creates symptoms related to systemic imbalance and functional strain, such as fever and painful urination. This primary use is relevant when short-term symptomatic assistance is needed.

Quick Fact: Relief for Localized Inflammation

“Tarivid supports patients during episodes of heightened discomfort by assisting with maintaining functional stability.” The medication is considered relevant in clinical settings marked by localized infections of the eye (like bacterial conjunctivitis and corneal ulcers) and the ear (otitis externa and specific middle ear infections). This therapy is applied in cases where symptoms cluster into patterns of discharge, pain, and inflammation that interfere with daily comfort. The overall therapeutic benefit is its role in managing the infection, which supports the body’s ability to clear the pathogen and generally contributes to improved comfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Tarivid (Ofloxacin)

The eligibility for Tarivid is strictly defined by regulatory documents, particularly concerning systemic (oral) versus topical (eye/ear) use.

Absolute Contraindications (Systemic Use)

Systemic use is contraindicated in several groups due to specific risks:

  • Patients with hypersensitivity to Ofloxacin or any other fluoroquinolone antibiotics.
  • Individuals with a history of tendon disorders related to prior fluoroquinolone use.
  • Patients with epilepsy or a known history of CNS disorders that lower the seizure threshold.
  • Children and growing adolescents (generally under 18 years) due to the risk of joint cartilage damage.
  • Pregnant and breastfeeding women.

Age-Related Eligibility

Population Systemic Use (Oral) Status Topical Use (Otic/Ophthalmic) Status
Pediatric Contraindicated (under 18 years) Approved for specific use starting as young as 6 months
Older Adults Requires special caution (increased risk of tendon rupture) Generally eligible; no specific adjustment necessary

Conditional or Restricted Use

Use requires special caution or mandatory dose modification in patients with impaired renal function (due to reduced clearance) or severe hepatic dysfunction. Additionally, caution is required for patients with risk factors for QT interval prolongation, those with myasthenia gravis, and patients taking corticosteroids, due to increased risk of serious adverse effects.

What should I know about interactions with other medicines?

Tarivid Interactions with other medicines and products

Official regulatory documents describe several key interaction domains for Tarivid (Ofloxacin), which require specific constraints on co-administration to maintain efficacy and prevent toxicity.

Interaction with Cation-Containing Products

Tarivid should not be taken simultaneously with products containing polyvalent cations such as aluminum- or magnesium-containing antacids, sucralfate, and supplements containing iron or zinc. Co-administration of these products can lead to a significant reduction in Ofloxacin absorption, thereby lowering the drug's concentration in the bloodstream. The official constraint requires that Ofloxacin be administered approximately 2 hours before or 2 hours after these cation-containing medicines.

Potential for Increased Toxicity

Interacting Product Category Official Constraint/Implication
Anticoagulants (e.g., Warfarin) Requires close monitoring of coagulation parameters (e.g., INR) due to a reported potentiation of anticoagulant effects and risk of bleeding.
QT-Prolonging Drugs Avoid co-administration with other agents that are known to prolong the QT interval (e.g., Class IA and III antiarrhythmics) due to an increased risk of serious cardiac arrhythmias.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Caution is advised, as co-administration may increase the risk of Central Nervous System (CNS) stimulation and seizures.
Theophylline The combination may lower the seizure threshold, though a significant pharmacokinetic inhibition of Theophylline clearance has not been consistently documented across all studies.

These constraints define the official drug interaction profile by addressing potential chelation-based loss of efficacy and additive risks of organ-specific toxicity, particularly affecting the renal, cardiovascular, and central nervous systems.

Mechanism of Action

Ofloxacin is a fluoroquinolone compound that exerts a bactericidal effect by targeting essential bacterial enzymes involved in DNA maintenance and replication.


Inhibition of Bacterial DNA Gyrase

The primary mechanistic domain involves modifying the early molecular steps of bacterial genetic processes by binding to and inhibiting DNA gyrase (Topoisomerase II). This enzyme is critical for introducing negative supercoils into the bacterial DNA, a process required for DNA unwinding, replication, and transcription. The resulting biochemical consequence is the cessation of DNA replication and transcription, leading to disruption of bacterial proliferation.


Disruption of Topoisomerase IV

The compound also engages a secondary mechanism by targeting Topoisomerase IV, another key enzyme within the bacterial system. This enzyme separates the replicated, interlinked DNA chromosomes during the final stage of cell division. Inhibition of Topoisomerase IV prevents the successful segregation of daughter DNA strands, leading to the accumulation of DNA breaks. This action influences the bacterial proliferation process, which contributes to the observed pharmacological effects.

Dosage and Administration Information

Tarivid (ofloxacin) film-coated tablets are taken orally and must be swallowed whole with water. They may be taken with or without food, as timing in relation to meals is not officially stipulated. The tablet's scoreline, if present, is intended only to facilitate breaking for ease of swallowing and should not be used to divide the tablet into half-doses.

Official Dosing and Frequency

The required dose and frequency depend on the specific infection being treated. The dosage ranges from a single dose of 400 mg for uncomplicated urethral gonorrhoea to a regimen of 200 mg to 400 mg taken once or twice daily for most other infections. For severe or complicated infections, a daily dose of up to 800 mg, divided into two doses, may be recommended.

Indication (Adults) Dose Frequency Duration
Complicated UTI, Pyelonephritis 200 mg (up to 400 mg) Twice daily 7–21 days
Uncomplicated Cystitis 200 mg or 400 mg Twice daily or Once daily 1–3 days
Acute Prostatitis 200 mg (up to 400 mg) Twice daily 2–4 weeks
Uncomplicated Gonorrhoea 400 mg Single dose 1 day

Special Administration Conditions

Age and Organ Function Rules: Tarivid is contra-indicated for use in children and growing adolescents. Dose adjustment is mandatory for adult patients with impaired renal function (Creatinine Clearance <50 ml/min) because of the primary route of drug excretion. For patients with severe liver function disorders (e.g., cirrhosis with ascites), the maximum daily dose must not exceed 400 mg.

Missed Dose: If a dose is missed, it should be taken as soon as possible, but two doses should not be taken at one time. If it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed.

Switching Therapy: Ofloxacin can be used to complete a course of therapy in patients who have shown initial improvement on intravenous ofloxacin.

Recent Clinical Evidence

Tarivid: Recent Clinical Evidence

Core Study Findings

Studies have explored the potential of ofloxacin (marketed as Tarivid) for use in bacterial infections, particularly those affecting the urinary tract, respiratory tract, and reproductive organs. Research has evaluated the drug's activity against a wide spectrum of bacteria, including common Gram-negative and some Gram-positive strains.

Key Areas of Research

Clinical trials have investigated the use of ofloxacin in several key indications, focusing on outcomes related to infection clearance and symptom resolution. Data from randomized controlled trials (RCTs) have compared ofloxacin with other standard therapies for certain infections.

Infection Type Noted Bacteriological Clearance Rates
Uncomplicated Urinary Tract Infections (UTIs) High rates reported in short-course regimens (e.g., 3–7 days)
Respiratory Tract Infections (e.g., Pneumonia) Favorable outcomes noted in multi-center studies
Pelvic Inflammatory Disease (PID) Demonstrated similar clinical effectiveness to certain combination therapies

Safety and Tolerability Observations

As a fluoroquinolone antibiotic, ofloxacin has been subject to extensive safety reviews, which have noted the risk of serious adverse reactions primarily involving the musculoskeletal and nervous systems. These reactions, while rare, can be disabling and potentially long-lasting.

  • Common Side Effects: Trials frequently reported gastrointestinal issues, headache, and dizziness.
  • Serious Events: Concerns have been raised regarding the potential for tendinitis and tendon rupture, peripheral neuropathy (nerve damage), and central nervous system effects. The risk is considered higher in patients over 60, those with kidney impairment, or those receiving corticosteroid treatment.
  • Contraindications: Clinical studies generally exclude participants with severe heart conditions or a history of tendon disorders. This class of antibiotics is typically reserved for cases where alternative treatments are not considered appropriate.

Frequently Asked Questions (FAQ)

Common questions about Tarivid (FAQ)


Q: Why is Tarivid only available by prescription?

A: Tarivid belongs to a class of antibiotics that are associated with a risk of serious side effects, as noted by regulatory bodies. Official warnings and usage restrictions generally reserve this medicine for specific infections when alternative treatments are not appropriate. This safety profile generally necessitates medical professional oversight, consistent with its prescription-only status.


Q: How quickly does Tarivid start to work after taking it?

A: According to official drug information, the maximum concentration of the active ingredient in the bloodstream is typically reached one to two hours after taking an oral dose. This concentration refers to the highest level of the drug detected in the bloodstream.


Q: If I feel better, is it necessary to finish the whole course of Tarivid?

A: Regulatory guidance advises that it is important to continue taking the medication for the full prescribed duration, even if your symptoms begin to improve or disappear entirely. This practice is aligned with general public health guidelines concerning the use of antibiotics to help manage bacterial susceptibility.


Q: Does Tarivid interact with alcohol?

A: Official patient information often suggests discussing the use of alcohol with a healthcare professional, as its use with this type of medicine may alter the risk of certain side effects. Patients should consult their prescribing healthcare provider for personalized guidance.


Q: Is Tarivid generally considered safe for people with liver disease?

A: Official documents note that patients with pre-existing liver problems or severe liver function disorders are advised to use the medication with caution. For patients with these conditions, official product information specifies a dose restriction for patients with severe liver function disorders.


Q: Can Tarivid cause strange dreams or hallucinations?

A: Yes. Official drug labels list hallucinations and psychotic reactions as serious central nervous system side effects that have been reported with this class of medicine. Patients and caregivers are generally advised to be alert to any changes in mood or unusual thoughts while using the medicine.


Q: Is Tarivid considered a penicillin antibiotic?

A: No. Tarivid’s active ingredient, Ofloxacin, is officially classified as a fluoroquinolone antimicrobial. This means it is chemically and structurally distinct from the penicillin family and other beta-lactam antibiotics.


Q: Can Tarivid treat stomach or gut infections?

A: Official drug labels primarily list indications related to the urinary tract, respiratory tract, and reproductive organs. Gastrointestinal infections are generally not listed as a primary approved indication in the core systemic (oral tablet) regulatory labeling.


Q: How long does the antibiotic effect of Tarivid last in the body?

A: The active ingredient, Ofloxacin, has a typical plasma elimination half-life of approximately 4 to 5 hours in healthy individuals. The half-life is the time it takes for the concentration of the medicine in the blood to drop by half.


Q: Can Tarivid affect my energy levels?

A: Official safety reviews and labeling mention fatigue and general unusual weakness as side effects that have been reported with this class of medicine. Patients experiencing significant changes in energy levels are advised to consult with their prescribing healthcare provider.


Q: Are there any specific supplements or vitamins that interact with Tarivid?

A: Regulatory documents explicitly warn against taking Tarivid simultaneously with supplements containing certain minerals like iron or zinc. These can significantly reduce the amount of the drug the body absorbs, making the treatment less effective.


Q: What foods or drinks should be avoided when taking Tarivid?

A: Tarivid tablets may be taken with or without food. However, official information states that it should not be taken at the same time as products containing certain polyvalent cations (such as aluminum and magnesium, often found in antacids) as this can reduce drug absorption. Some enteral feedings have also been noted to reduce absorption.


Q: Can Tarivid be used for preventing bacterial infections?

A: Official drug labels state that Tarivid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. While the label mentions both treatment and prevention, official use is often restricted, focusing on treating established infections.


Q: What is the difference between Tarivid and Ciprofloxacin?

A: Tarivid (Ofloxacin) and Ciprofloxacin are both distinct compounds classified within the same group: fluoroquinolone antibiotics. As they are in the same drug class (fluoroquinolones), official documents often group them when issuing class warnings related to safety.


Q: Why do official documents warn about mental health side effects with Tarivid?

A: Official documents include these warnings because there have been reports of serious psychiatric reactions that may occur, including depression, anxiety, and psychosis. These reactions, while rare, may occur sometimes soon after beginning treatment.


Q: Can Tarivid cause sensitivity to light?

A: Yes. Official safety data lists photosensitization (increased sensitivity to sunlight) as an adverse effect of the drug. Patients are advised in the product information to take precautions regarding sun exposure.


Q: Do studies support Tarivid's use for treating eye infections?

A: Yes. The active ingredient in Tarivid is FDA-approved and commonly used in a specialized ophthalmic (eye drop) form. This topical solution is used to treat bacterial infections of the eye, such as conjunctivitis and corneal ulcers.


Q: What research is available on the long-term effects of Tarivid?

A: Regulatory agencies have noted that some serious adverse reactions, such as tendon damage and nerve damage (neuropathy), can be disabling and potentially permanent. These effects may occur soon after beginning treatment or up to several months after stopping the medication. This information has led to updated warnings from regulatory bodies.


Q: Is there a generic version of Tarivid available?

A: Yes. The active ingredient, Ofloxacin, has been approved by the FDA as a generic version for commercial use. This generic is available in various forms, including tablets for systemic use and solutions for localized use.


Q: Is it possible to become resistant to Tarivid over time?

A: Regulatory information notes that the development of drug-resistant bacteria is a concern with all antibiotic treatments. The official label specifies that the medicine should be used for infections caused by bacteria determined to be susceptible to the drug.


Q: What are the signs that Tarivid is working for an infection?

A: Official studies and guidelines for the drug’s use focus on two main outcomes: infection clearance (meaning the bacteria are eliminated) and symptom resolution. Signs that the treatment is working include improvement in symptoms such as fever, pain, or inflammation.


Q: Do official documents list a restriction on driving while taking Tarivid?

A: Regulatory patient information advises that this medicine may affect your coordination, reaction time, or judgment. Patients are generally cautioned against driving or operating complex machinery until they understand the full effects of the medication on them.


Q: Is Tarivid ever prescribed for skin infections?

A: Yes. Official drug labels list uncomplicated skin and skin structure infections as one of the approved indications for systemic (oral tablet) use.


Q: Does Tarivid contain any common allergens like lactose or gluten?

A: Regulatory documents state that each film-coated tablet contains lactose as an inactive ingredient. The official contraindication section includes hypersensitivity to any of the excipients (inactive ingredients). The tablets are also essentially 'sodium-free'.


Q: Why is Tarivid listed with a Black Box Warning in some countries?

A: The FDA’s Boxed Warning, which is the strongest caution, was revised to address the risk of disabling and potentially permanent side effects. These severe effects can involve the tendons, muscles, joints, nerves, and the central nervous system.

How should Tarivid be stored and disposed of?

Tarivid (Ofloxacin) must be stored and disposed of according to official regulatory labeling to maintain product stability and ensure safety.

Storage Conditions

Tarivid tablets must be stored at a temperature not exceeding 30°C. Ophthalmic solutions generally require storage at room temperature and should be kept away from excess heat and moisture. It is specifically instructed not to refrigerate or freeze certain liquid forms. The medication must remain in its original container and be kept tightly closed.

Handling and Safety

All forms of Tarivid must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Tarivid must be disposed of in accordance with local regulations for pharmaceutical waste. If local collection programs are unavailable, official guidelines recommend mixing the medicine with an undesirable substance (such as dirt) and sealing it in a container before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tarivid found in:

A-Z Index: